Results 1 to 10 of about 30,112 (235)

Surgical staging of apparent early-stage ovarian mucinous carcinoma [PDF]

World Journal of Surgical Oncology, 2022
Objectives The aim of the study was to explore the rate of upstaging after complete surgical staging among patients with apparent FIGO stage I ovarian mucinous carcinoma.
Zhen Yuan, Ying Zhang, Dongyan Cao, Keng Shen   +3 more
doaj   +4 more sources

Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature [PDF]

Journal of Ovarian Research, 2021
Background In ovarian mucinous carcinoma, invasive pattern is the important factor but there were less reposts to investigate it. The aim of this study was to examine the association between prognosis and invasive patterns of ovarian mucinous carcinoma ...
Taira Hada, Morikazu Miyamoto, Hiroki Ishibashi, Hiroko Matsuura, Takahiro Sakamoto, Soichiro Kakimoto, Hideki Iwahashi, Hitoshi Tsuda, Masashi Takano   +8 more
doaj   +2 more sources

Prognostic similarity between ovarian mucinous carcinoma with expansile invasion and ovarian mucinous borderline tumor: A retrospective analysis. [PDF]

Medicine (Baltimore), 2021
Abstract There is a similarity of histological features and survival between ovarian mucinous carcinoma (MC) with expansile invasion and ovarian mucinous borderline tumor (MBT). The aim of this study was to compare the clinical outcomes of MC with expansile invasion with those of MBT based on the 2020 World Health Organization (
Hada T, Miyamoto M, Ishibashi H, Matsuura H, Sakamoto T, Kakimoto S, Iwahashi H, Suzuki R, Sato K, Tsuda H, Takano M.   +10 more
europepmc   +4 more sources

Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment

Heliyon, 2023
Mucinous ovarian carcinoma (MOC) is a rare histological type of epithelial ovarian cancer. It has poor response to conventional platinum-based chemotherapy regimens and PARPi-based maintenance treatment, resulting in short survival and poor prognosis in ...
Yicong Wang, Lifeng Liu, Yongai Yu
doaj   +3 more sources

Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies [PDF]

Gynecologic Oncology Reports
Objective: Mucinous ovarian carcinoma (MOC) is a rare histologic subtype of ovarian cancer. While prognosis of early stage disease is excellent, novel treatment options are needed for advanced stage and recurrent MOC, which are associated with poor ...
Minyoung Jang, Stefan Gysler, Nawar A. Latif, Emily M. Ko, Robert L. Giuntoli, II, Sarah H. Kim, Fiona Simpkins, Dimitrios Nasioudis   +7 more
doaj   +2 more sources

Rare leptomeningeal recurrence of mucinous ovarian carcinoma

Gynecologic Oncology Reports
Ovarian cancer is the fifth most common cause of cancer death in women and represents the deadliest of the gynecologic cancers. Despite treatment, 80 % of patients diagnosed with ovarian cancer will experience recurrence of disease within 18 months ...
Gabrielle LeBlanc, Sarah G. Bell, William Delfyett, Brian Enloe, Madeleine Courtney-Brooks, Michelle Boisen   +5 more
doaj   +3 more sources

Bilateral mucinous ovarian carcinoma in a young female with tumor weighing 41.1 kg

Journal of Family Medicine and Primary Care, 2022
Mucinous ovarian carcinoma is a less-prevalent subtype of epithelial tumors. We present a case of giant mucinous ovarian carcinoma weighing 41.1 kg in a 24-year-old Indian girl. Benign mucinous tumors have the potential to reach an enormous size but such
Kavita Khoiwal, Payal Kumari, Deepika Dhundi, Om Kumari, Anshu Gupta, Priyanka Gupta, Sonu Sama, Pankaj Sharma, Michael Anthony, Amrita Gaurav, Jaya Chaturvedi   +10 more
doaj   +1 more source

Therapeutic options for mucinous ovarian carcinoma [PDF]

Gynecologic Oncology, 2020
Mucinous ovarian carcinoma (MOC) is an uncommon ovarian cancer histotype that responds poorly to conventional chemotherapy regimens. Although long overall survival outcomes can occur with early detection and optimal surgical resection, recurrent and advanced disease are associated with extremely poor survival.
Kylie L. Gorringe, Dane Cheasley, Matthew J. Wakefield, Georgina L. Ryland, Prue E. Allan, Kathryn Alsop, Kaushalya C. Amarasinghe, Sumitra Ananda, David D.L. Bowtell, Michael Christie, Yoke-Eng Chiew, Michael Churchman, Anna DeFazio, Sian Fereday, C. Blake Gilks, Charlie Gourley, Alison M. Hadley, Joy Hendley, Sally M. Hunter, Scott H. Kaufmann, Catherine J. Kennedy, Martin Köbel, Cecile Le Page, Jason Li, Richard Lupat, Orla M. McNally, Jessica N. McAlpine, Jan Pyman, Simone M. Rowley, Carolina Salazar, Hugo Saunders, Timothy Semple, Andrew N. Stephens, Niko Thio, Michelle C. Torres, Nadia Traficante, Magnus Zethoven, Yoland C. Antill, Ian G. Campbell, Clare L. Scott   +39 more
openaire   +4 more sources

Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel

Gynecologic Oncology Reports, 2023
Patients with advanced stage or recurrent mucinous ovarian carcinoma exhibit poor response to standard platinum- and taxane-based chemotherapy and poor prognosis.
Alexander J. Neil, Michael G. Muto, David L. Kolin, Panagiotis A. Konstantinopoulos   +3 more
doaj   +1 more source

Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?

Journal of Ovarian Research, 2023
Background 2020 World Health Organization Classification of Female Genital Tumors removed ovarian seromucinous carcinoma as a distinct entity and recategorized it as ovarian endometrioid carcinoma with mucinous differentiation according to its ...
Yi Hu, Kun Fu, Huining Liu, Qiongqiong He, Xiaoqin Qiu, Wenqing Yang, Yu Zhang   +6 more
doaj   +1 more source